RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Hiroshi Matsui to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications Hiroshi Matsui has written about Xenograft Model Antitumor Assays.
Hiroshi Matsui
Connection Strength
0.088
Xenograft Model Antitumor Assays
  1. Chen Q, Dorji JP, Perera SG, Li P, Aijaz F, Ihuoma LC, Matsui H, Awah CU. In vivo inhibition of c-MYC in the metastatic drug-resistant ovarian cancer cells down regulates the c-MYC-PD-L1-PAX8-p21 to achieve therapeutic efficacy. BMC Cancer. 2025 Dec 10; 26(1):68.
    View in: PubMed
    Score: 0.053
  2. Raghubir M, Rahman CN, Fang J, Matsui H, Mahajan SS. Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice. Oncol Rep. 2020 01; 43(1):169-176.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support